New strategies for allogeneic BMT
Author:
- 1 August 2003
- journal article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 32 (S1) , S73-S75
Abstract
In humans, the success rate of BMT across major histocompatibility complex (MHC) barriers is lowered by graft-versus-host disease (GvHD), graft rejection and incomplete T-cell recovery. To prevent GvHD, we attempted to minimize the contamination of bone marrow cells (BMCs) with T cells from the peripheral blood when donor BMCs were collected, finally establishing a new 'Perfusion Method' using cynomolgus monkeys. There was significantly less contamination of BMCs with T cells in this method (20%) consisting of multiple aspirations of BMCs from the iliac crest. Using radio-sensitive and chimerism-resistant MRL/lpr mice, we also established a new method for allogeneic (allo) BMT and organ allografts. In this method, whole BMCs, containing a small number of T cells and mesenchymal stem cells (MSCs), were directly injected into the bone marrow cavity (intrabone marrow [IBM]-BMT). MRL/lpr mice treated with IBM-BMT survived more than 2 years without showing the symptoms of autoimmune diseases. IBM-BMT thus has several advantages: (i) no GvHD develops even if T cells are not depleted from BMCs; (ii) no graft failure occurs even if the dose of radiation as the conditioning regimen for allo BMT is reduced to 5Gy 2; (iii) hemopoietic recovery is rapid; and (iv) the restoration of T-cell functions is quick and complete even in donor–recipient combinations across MHC barriers. We believe that these strategies for allo BMT and organ allografts herald a new era in transplantation, and that they would be helpful in allogeneic HSCT of autoimmune diseases.Keywords
This publication has 14 references indexed in Scilit:
- Prevention of Senile Osteoporosis in SAMP6 Mice by Intrabone Marrow Injection of Allogeneic Bone Marrow CellsStem Cells, 2002
- Treatment of streptozotocin-induced diabetes mellitus by transplantation of islet cells plus bone marrow cells via portal vein in rats1Transplantation, 2002
- Treatment of autoimmune diseases by hematopoietic stem cell transplantationExperimental Hematology, 2001
- A NOVEL STRATEGY FOR ORGAN ALLOGRAFTS USING SUBLETHAL (7 Gy) IRRADIATION FOLLOWED BY INJECTION OF DONOR BONE MARROW CELLS VIA PORTAL VEIN1Transplantation, 2001
- Crucial Role of Donor‐Derived Stromal Cells in Successful Treatment for Intractable Autoimmune Diseases in MRL/lpr Mice by BMT Via Portal VeinStem Cells, 2001
- Long-term observations of autoimmune-prone mice treated for autoimmune disease by allogeneic bone marrow transplantation.Proceedings of the National Academy of Sciences, 1989
- Treatment of type 1 diabetes mellitus in non-obese diabetic mice by transplantation of allogeneic bone marrow and pancreatic tissue.Proceedings of the National Academy of Sciences, 1987
- Successful liver allografts in mice by combination with allogeneic bone marrow transplantation.Proceedings of the National Academy of Sciences, 1986
- Prevention of type I diabetes in nonobese diabetic mice by allogenic bone marrow transplantation.Proceedings of the National Academy of Sciences, 1985
- Rationale for bone marrow transplantation in the treatment of autoimmune diseases.Proceedings of the National Academy of Sciences, 1985